Q32 Bio (QTTB) Company presentation summary

Strategic focus and pipeline

• Advancing immune therapeutics with a lead focus on alopecia areata (AA) using bempikibart, an IL-7Ra antagonist antibody with dual IL-7/TSLP inhibition and a differentiated safety profile compared to JAK inhibitors.

• Pipeline includes wholly-owned programs in inflammatory and autoimmune diseases, with bempikibart in Phase 2a for AA and complement inhibitor assets, including ADX-097 (sold to Akebia) and ADX-096, under strategic review.

• Management team has deep expertise in inflammation, autoimmunity, and public biotech operations.

Clinical development and results

• SIGNAL-AA Phase 2a Part A showed durable hair regrowth and favorable safety in severe/very severe AA, with responses persisting up to 7 months post-treatment.

• Part B is fully enrolled, using a loading regimen for faster steady-state drug levels; 36-week topline results expected mid-2026.

• Bempikibart demonstrated robust changes in Th2 biomarkers (TARC, IgE, eosinophils) and CD3+ T cells, supporting its mechanism and potential for expansion into other indications.

• No Grade 3 or higher related adverse events or infections reported; safety profile supports use in patients ineligible for JAK inhibitors.

Market opportunity and positioning

• AA affects 700,000 people in the US, with a projected $2.6B market by 2030; current therapies lack desired safety and durability.

• Bempikibart aims to offer a paradigm shift with potential for long-term remission and a favorable safety profile, addressing significant unmet need.

• Product profile includes subcutaneous dosing, no black box warning, and potential for first-line use.